Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients

Journal of Infectious Diseases

Volumn 185, Issue SUPPL. 2, 2002, Pages

  Dieterich, Douglas T ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIDEPRESSANT AGENT; ANTIDIARRHEAL AGENT; ANTIEMETIC AGENT; DIDANOSINE; INDINAVIR; NELFINAVIR; NONSTEROID ANTIINFLAMMATORY AGENT; NUCLEOSIDE ANALOG; PARACETAMOL; PROTEINASE INHIBITOR; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; RITONAVIR; SEROTONIN UPTAKE INHIBITOR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANEMIA; ARTICLE; CLINICAL TRIAL; COMORBIDITY; DISEASE COURSE; DRUG ANTAGONISM; DRUG EFFICACY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA; LIVER INJURY; LIVER TOXICITY; MENTAL DISEASE; MORTALITY; PERINATAL INFECTION; PRIORITY JOURNAL; SEXUAL TRANSMISSION; VIRUS LOAD;

ANEMIA, HEMOLYTIC; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; EPOETIN ALFA; HEMATINICS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; RIBAVIRIN;

EID: 0036252557     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/340199     Document Type: Article

References (70)

1. Antiretroviral therapy and declining AIDS mortality in New York City
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
3. Natural history of HIV infection in the era of combination antiretroviral therapy
4. Hepatitis C virus and human immunodeficiency virus: Clinical issues in coinfection
5. Increasing mortality due to end-stage liver disease in patients with immunodeficiency virus infection
6. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
7. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta VA (Veterans Affairs Medical Center) Cohort Study (HAVACS): The effect of coinfection on survival
8. Hepatitis C virus/human immunodeficiency virus coinfection: Clinical management issues
9. Hepatitis C. Prevalence in HIV-infected patients: A cross sectional analysis of the US Adult Clinical Trials Group
10. Hepatitis C virus genotypes and quasispecies
11. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
12. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study
13. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission
14. Increased vertical transmission of human immunodeficiency virus from hepatitis C virus-coinfected mothers. Women and Infants Transmission Study
15. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease
16. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
17. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy
18. + T-cell responses in long-term recovered and chronically infected patients [abstract]
19. Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers
20. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy
21. 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C
22. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
23. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)
24. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
25. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy
26. Viral kinetics and mathematical models
27. Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes
28. Hepatitis C virus (HCV) dynamics during induction therapy with interferon (IFN) alpha and/or ribavirin [abstract ]
29. + cell count
30. Recombinant interferon-alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. Comite des Anti-Viraux
31. Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus
32. Ribavirin antagonizes the effect of azidothymidine on HIV replication
33. Ribavirin antagonizes inhibitory effects of pyrimidine 2′,3′-dideoxynucleosides but enhances inhibitory effects of purine 2′,3′-dideoxynucleosides on replication of human immunodeficiency virus in vitro
34. Mechanism of the potentiating effect of ribavirin on the activity of 2′,3′-dideoxyinosine against human immunodeficiency virus
35. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team
36. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection
37. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe
38. A case-control study to examine the association of anemia with HIV/AIDS progression: Results from the 1996 enrollment cohort [abstract 318]
39. Anemia in HIV disease in the HAART era: Is it common? [abstract]
40. Relationship between highly active anti-retroviral therapy (HAART) and anemia in a large cohort of HIV infected women (Women's Interagency HIV Study - WIHS) [abstract]
41. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia
42. Epoetin alfa therapy for anaemia in HIV-infected patients: Impact on quality of life
43. Community HIV Anemia Management Protocol Sites (CHAMPS). Once-weekly dosing of epoetin alfa increases hemoglobin and quality of life in HIV-positive patients with anemia [abstract 509]
44. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: Results from the multistate adult and adolescent spectrum of HIV disease surveillance project
45. Anemia and survival in HIV infection
46. Relationship between highly active anti-retroviral therapy (HAART), anemia and survival in a large cohort of HIV infected women (Women's Interagency HIV Study - WIHS)
47. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients
48. Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: An early report
49. Chronic hepatitis C in HIV infection: Feasibility and sustained efficacy of therapy with interferon alfa-2b and tribavirin
50. Combination treatment with interferon (IFN) and ribavirin (RBV) for hepatitis C (HCV) in co-infection patients [abstract]
51. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients
52. The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2b in combination with ribavirin [abstract]
53. The effect of long-term treatment with granulocyte colony-stimulating factor on hematopoiesis in HIV-infected individuals
54. + T cell counts of human immunodeficiency virus-infected patients receiving stable, highly active antiretroviral therapy: Results from a randomized, placebo-controlled trial
55. Mechanisms of transfusion-induced immunosuppression
56. Paroxetine for the prevention of depression induced by high-dose interferon alfa
57. Consensus statement: Anemia in HIV infection - Current trends, treatment options, and practice strategies
58. Hematologic complications of human immunodeficiency virus infection and the acquired immunodeficiency syndrome
59. + lymphocytes as prognostic markers of HIV-I infection
60. Use of blood transfusion in management of anemia
61. Human immunodeficiency virus type 1 activation after blood transfusion
62. Transfusion of blood components to persons infected with human immunodeficiency virus type 1: Relationship to opportunistic infection
63. Diminished helper/suppressor lymphocyte ratios and natural killer activity in recipients of repeated blood transfusions
64. The effect of blood transfusion on T-suppressor cells in renal dialysis patients
65. Characterization and biological effects of recombinant human erythropoietin
66. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia
67. Epoetin alfa improves the quality of life (QOL) in HIV patients with anemia [abstract]
68. Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis